一例严重的免疫检查点抑制剂相关的胃炎,用类固醇和因弗力西马布治疗
Koki Tanaka1, Toshiyuki Morisawa1, Norio Katayama1
1Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Internal medicine (Tokyo, Japan)
|September 18, 2025
概括
一名77岁的老人患上了严重的免疫相关的胃炎,因为肺癌的 pembrolizumab. 随着INFLIXIMAB的添加,类固醇耐药性胃炎显著改善,显示了其在控制这种副作用方面的价值.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 免疫检查点抑制剂如 pembrolizumab 越来越多地用于肺癌.
- 免疫相关的不良事件 (irAEs),包括胃炎,可以发生在这些疗法.
- 胃炎可能是严重的,可能对初始治疗没有反应.
研究的目的:
- 报告严重的免疫相关胃炎病例.
- 为了突出管理类固醇耐药病例的挑战.
- 为了强调infliximab在耐药性免疫相关胃炎中的作用.
主要方法:
- 一份病例报告显示,一名77岁的男性肺癌患者接受了 pembrolizumab 的治疗.
- 临床表现,内镜检查结果,以及胃炎的组织学检查.
- 评估对初始类固醇治疗的反应和随后添加infliximab的反应.
主要成果:
- 患者患有严重的与免疫相关的胃炎,对类固醇无反应 (类固醇耐药).
- 与类固醇和infliximab的联合治疗导致了显著的临床和内镜改善.
- 早期内镜和组织学诊断至关重要.
结论:
- 免疫相关的胃炎是pembrolizumab的一个潜在的严重副作用.
- 早期诊断和及时评估治疗反应至关重要.
- 因弗利克西马布是治疗类固醇耐药性免疫相关胃炎的有效救援疗法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Gastritis III: Clinical Manifestations and Management
1.2K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.2K


